首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   222篇
  免费   17篇
  国内免费   9篇
儿科学   3篇
基础医学   15篇
口腔科学   1篇
临床医学   42篇
内科学   67篇
皮肤病学   3篇
神经病学   16篇
特种医学   1篇
外科学   64篇
综合类   3篇
预防医学   12篇
药学   13篇
肿瘤学   8篇
  2023年   1篇
  2022年   5篇
  2021年   11篇
  2020年   4篇
  2019年   6篇
  2018年   5篇
  2017年   7篇
  2016年   2篇
  2015年   5篇
  2014年   10篇
  2013年   8篇
  2012年   13篇
  2011年   23篇
  2010年   8篇
  2009年   10篇
  2008年   16篇
  2007年   11篇
  2006年   21篇
  2005年   12篇
  2004年   10篇
  2003年   7篇
  2002年   2篇
  2001年   1篇
  1999年   6篇
  1997年   2篇
  1996年   1篇
  1992年   2篇
  1991年   2篇
  1990年   4篇
  1989年   3篇
  1988年   3篇
  1987年   3篇
  1986年   3篇
  1985年   4篇
  1984年   1篇
  1983年   1篇
  1982年   1篇
  1981年   4篇
  1980年   1篇
  1979年   1篇
  1977年   1篇
  1975年   1篇
  1974年   1篇
  1973年   1篇
  1971年   1篇
  1970年   2篇
  1967年   1篇
排序方式: 共有248条查询结果,搜索用时 15 毫秒
1.
2.
3.

Summary

The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs constitute the conventional therapy for the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS), but are often problematic, owing to the variable sensitivity of thromboplastins to lupus anticoagulant. Thus, the International Normalized Ratio may not accurately reflect anticoagulation intensity, or be clinically effective. Definition of the current role of DOACs in the treatment of APS is based on limited clinical trial data and information from other sources, including manufacturers’ data, case series or cohort studies, and expert consensus. The Rivaroxaban in Antiphospholipid Syndrome (RAPS) randomized controlled trial (RCT), which had a laboratory surrogate primary outcome measure, suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic APS patients with a single venous thromboembolism event requiring standard‐intensity anticoagulation. However, further studies, in particular to provide better long‐term efficacy and safety data, are needed before it can be widely recommended. APS patients are clinically heterogeneous, with the risk of recurrent thrombosis and the intensity of anticoagulation being influenced by their clinical phenotype and risk profile. DOAC trials involving homogeneous thrombotic APS populations, with the antiphospholipid antibody status well defined, will help to optimize the appropriate treatment in APS patient subgroups. Ongoing and emerging DOAC RCTs should provide further information to guide the use of DOACs in APS patients. Optimal identification of APS patients is a key step in working towards improved therapeutic strategies in these individuals.
  相似文献   
4.
5.
In June 2010, a severe outbreak of 13 cases of post-cataract surgery endophthalmitis caused by multidrug-resistant Pseudomonas aeruginosa occurred. Pulse-field gel electrophoresis in eye isolates found 95% genetic similarity; however, extensive environmental and carriage investigation revealed no source of infection.  相似文献   
6.
7.
8.
9.
This narrative review presents the findings from intervention studies on the effects of sleep deprivation on eating habits, metabolic rate, and the hormones regulating metabolism, and discusses their relevance to weight loss efforts. Disturbed sleeping patterns lead to increased energy intake, partly from excessive snacking, mainly on foods high in fat and carbohydrates. The studies focused mainly on the effects of sleep duration, but also of sleep quality, on dietary intake during weight loss trials, and on weight loss maintenance. It is important to explore sleep routines that could enhance the efforts of obese and overweight people to lose weight, maintain their weight loss, and improve their overall health.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号